Skip to main content
Erschienen in:

01.12.2013 | CME Zertifizierte Fortbildung

Spätfolgen onkologischer Therapie

verfasst von: Dr. H. Biersack, G. Brabant

Erschienen in: Die Onkologie | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Spätschäden einer Krebserkrankung sind durch die therapiebedingt verbesserten Überlebensraten ein rasch zunehmendes, aber bislang zu wenig wahrgenommenes Problem. Zu diesen Folgeerkrankungen, die definitionsgemäß Jahre nach der initialen Erkrankung auftreten, zählen nicht nur Zweittumoren, sondern auch eine Reihe nichtonkologischer internistischer Probleme. Diese kardiovaskulären, gastrointestinalen, renalen oder endokrinen Spätschäden wurden bislang unzureichend beachtet und müssen bei der häufig schleichenden Symptomatik gezielt adressiert werden.
Literatur
1.
Zurück zum Zitat Chemaitilly W, Sklar CA (2010) Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 17:R141–R159PubMedCrossRef Chemaitilly W, Sklar CA (2010) Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 17:R141–R159PubMedCrossRef
2.
Zurück zum Zitat Diller L, Chow EJ, Gurney JG et al (2009) Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol 27:2339–2355PubMedCrossRef Diller L, Chow EJ, Gurney JG et al (2009) Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol 27:2339–2355PubMedCrossRef
3.
Zurück zum Zitat Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582PubMedCrossRef Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582PubMedCrossRef
4.
Zurück zum Zitat Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR (2012) Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 118(8 Suppl):2270–2276. doi:10.1002/cncr.27462. (Review. PubMed PMID: 22488701)PubMedCrossRef Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR (2012) Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 118(8 Suppl):2270–2276. doi:10.1002/cncr.27462. (Review. PubMed PMID: 22488701)PubMedCrossRef
5.
Zurück zum Zitat Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72–85PubMed Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72–85PubMed
6.
Zurück zum Zitat Adams MJ, Hardenbergh PH, Constine LS et al (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45:55–75PubMedCrossRef Adams MJ, Hardenbergh PH, Constine LS et al (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45:55–75PubMedCrossRef
7.
Zurück zum Zitat Reinders JG, Heijmen BJ, Olofsen-van Acht MJ et al (1999) Ischemic heart disease after mantlefield irradiation for Hodgkin’s disease in long-term follow-up. Radiother Oncol 51:35–42PubMedCrossRef Reinders JG, Heijmen BJ, Olofsen-van Acht MJ et al (1999) Ischemic heart disease after mantlefield irradiation for Hodgkin’s disease in long-term follow-up. Radiother Oncol 51:35–42PubMedCrossRef
8.
Zurück zum Zitat Travis LB, Beard C, Allan JM et al (2010) Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 102:1114–1130PubMedCrossRef Travis LB, Beard C, Allan JM et al (2010) Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 102:1114–1130PubMedCrossRef
9.
Zurück zum Zitat Griffith ML, Savani BN, Boord JB (2010) Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 116:1197–1204PubMedCrossRef Griffith ML, Savani BN, Boord JB (2010) Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 116:1197–1204PubMedCrossRef
10.
Zurück zum Zitat Bathia S, Constine LS (2009) Late morbidity after successful treatment of children with cancer. Cancer J 15:174–180CrossRef Bathia S, Constine LS (2009) Late morbidity after successful treatment of children with cancer. Cancer J 15:174–180CrossRef
11.
Zurück zum Zitat Zhang Y, Goddard K, Spinelli JJ et al (2012) Risk of late mortality and second malignant neoplasms among 5-year survivors of young adult cancer: a report of the Childhood, Adolescent, and Young Adult Cancer Survivors Research Program. J Cancer Epidemiol 2012:103032PubMed Zhang Y, Goddard K, Spinelli JJ et al (2012) Risk of late mortality and second malignant neoplasms among 5-year survivors of young adult cancer: a report of the Childhood, Adolescent, and Young Adult Cancer Survivors Research Program. J Cancer Epidemiol 2012:103032PubMed
12.
Zurück zum Zitat Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. The Renal Insufficiency and Anticancer Medications (IRMA) Study. Cancer 110:1376–1384PubMedCrossRef Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. The Renal Insufficiency and Anticancer Medications (IRMA) Study. Cancer 110:1376–1384PubMedCrossRef
13.
Zurück zum Zitat Fosså SD, Aass N, Winderen M et al (2002) Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13:222–228 (PubMed PMID: 11885998) Fosså SD, Aass N, Winderen M et al (2002) Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13:222–228 (PubMed PMID: 11885998)
14.
Zurück zum Zitat Skinner R (2011) Nephrotoxicity – what do we know and what don’t we know? J Pediatr Hematol Oncol 33:128–134PubMedCrossRef Skinner R (2011) Nephrotoxicity – what do we know and what don’t we know? J Pediatr Hematol Oncol 33:128–134PubMedCrossRef
15.
Zurück zum Zitat Goldsby R, Chen Y, Raber S et al (2011) Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. Gastroenterology 140:1464.e1–1471.e1. doi:10.1053/j.gastro.2011.01.049 (Epub 2011 Mar 17 PubMed PMID: 21315721; PubMed Central PMCID: PMC3081911)PubMedCrossRef Goldsby R, Chen Y, Raber S et al (2011) Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. Gastroenterology 140:1464.e1–1471.e1. doi:10.1053/j.gastro.2011.01.049 (Epub 2011 Mar 17 PubMed PMID: 21315721; PubMed Central PMCID: PMC3081911)PubMedCrossRef
16.
Zurück zum Zitat Andreyev HJ (2011) „Pelvic radiation disease“: new understanding and new solutions for a new disease in the era of cancer survivorship. Scand J Gastroenterol 46:389–397PubMedCrossRef Andreyev HJ (2011) „Pelvic radiation disease“: new understanding and new solutions for a new disease in the era of cancer survivorship. Scand J Gastroenterol 46:389–397PubMedCrossRef
17.
Zurück zum Zitat Juszczak A, Gupta A, Karavitaki N et al (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1–5PubMedCrossRef Juszczak A, Gupta A, Karavitaki N et al (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1–5PubMedCrossRef
18.
Zurück zum Zitat Darzy KH (2009) Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 5:88–99PubMedCrossRef Darzy KH (2009) Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 5:88–99PubMedCrossRef
19.
Zurück zum Zitat Oberfield SE, Soranno D, Nirenberg A et al (1996) Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adolesc Med 150:589–592PubMedCrossRef Oberfield SE, Soranno D, Nirenberg A et al (1996) Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adolesc Med 150:589–592PubMedCrossRef
20.
Zurück zum Zitat Ellison DH, Berl T (2007) Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 356:2064–2072PubMedCrossRef Ellison DH, Berl T (2007) Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 356:2064–2072PubMedCrossRef
21.
Zurück zum Zitat Pai HH, Thornton A, Katznelson L et al (2001) Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 49:1079–1092PubMedCrossRef Pai HH, Thornton A, Katznelson L et al (2001) Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 49:1079–1092PubMedCrossRef
22.
Zurück zum Zitat Brabant G, Poll EM, Jönsson P et al (2009) Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations? Eur J Endocrinol 161(Suppl 1):S25–S31PubMedCrossRef Brabant G, Poll EM, Jönsson P et al (2009) Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations? Eur J Endocrinol 161(Suppl 1):S25–S31PubMedCrossRef
23.
Zurück zum Zitat Feldt S, Schüssel K, Quinzler R et al (2012) Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer 48:974–981PubMedCrossRef Feldt S, Schüssel K, Quinzler R et al (2012) Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer 48:974–981PubMedCrossRef
24.
Zurück zum Zitat Wallace WH, Shalet SM, Crowne EC et al (1989) Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol (R Coll Radiol) 1:75–79 Wallace WH, Shalet SM, Crowne EC et al (1989) Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol (R Coll Radiol) 1:75–79
25.
Zurück zum Zitat Koyama H, Wada T, Nishizawa Y et al (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403–1409PubMedCrossRef Koyama H, Wada T, Nishizawa Y et al (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403–1409PubMedCrossRef
26.
Zurück zum Zitat Green DM, Kawashima T, Stovall M et al (2009) Fertility of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 27:2677–2685PubMedCrossRef Green DM, Kawashima T, Stovall M et al (2009) Fertility of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 27:2677–2685PubMedCrossRef
27.
Zurück zum Zitat Lee SJ, Schover LR, Partridge AH et al (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931PubMedCrossRef Lee SJ, Schover LR, Partridge AH et al (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931PubMedCrossRef
28.
Zurück zum Zitat Rowley MJ, Leach DR, Warner GA, Heller CG (1974) Effect of graded doses of ionizing radiation on the human testis. Radiat Res 59:665–678PubMedCrossRef Rowley MJ, Leach DR, Warner GA, Heller CG (1974) Effect of graded doses of ionizing radiation on the human testis. Radiat Res 59:665–678PubMedCrossRef
29.
Zurück zum Zitat Georgiou KR, Scherer MA, Fan CM et al (2011) Methotrexate chemotherapy reduces osteogenesis but increases adipogenesis potential in the bone marrow. J Cell Physiol Georgiou KR, Scherer MA, Fan CM et al (2011) Methotrexate chemotherapy reduces osteogenesis but increases adipogenesis potential in the bone marrow. J Cell Physiol
30.
Zurück zum Zitat Wagner LM, Neel MD, Pappo AS et al (2001) Fractures in pediatric Ewing sarcoma. J Pediatr Hematol Oncol 23:568–571PubMedCrossRef Wagner LM, Neel MD, Pappo AS et al (2001) Fractures in pediatric Ewing sarcoma. J Pediatr Hematol Oncol 23:568–571PubMedCrossRef
31.
Zurück zum Zitat Einenauer DA, Bredenfeld H, Haverkamp H et al (2009) Hodgkin’s lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J Clin Oncol 27:6079–6085CrossRef Einenauer DA, Bredenfeld H, Haverkamp H et al (2009) Hodgkin’s lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J Clin Oncol 27:6079–6085CrossRef
32.
Zurück zum Zitat Green DM, Hyland A, Barcos MP et al (2000) Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol 18:1492–1499PubMed Green DM, Hyland A, Barcos MP et al (2000) Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol 18:1492–1499PubMed
33.
Zurück zum Zitat Majhail NS (2011) Secondary cancers following allogeneic haematopoietic cell transplantation in adults. Br J Haematol 154:301–310PubMedCrossRef Majhail NS (2011) Secondary cancers following allogeneic haematopoietic cell transplantation in adults. Br J Haematol 154:301–310PubMedCrossRef
34.
Zurück zum Zitat Bari A, Marcheselli L, Marcheselli R et al (2011) Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. Mediterr J Hematol Infect Dis 3:e2011065PubMedCrossRef Bari A, Marcheselli L, Marcheselli R et al (2011) Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. Mediterr J Hematol Infect Dis 3:e2011065PubMedCrossRef
35.
Zurück zum Zitat Le Deley M-C, Suzan F, Butull B et al (2007) Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25:292–300CrossRef Le Deley M-C, Suzan F, Butull B et al (2007) Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25:292–300CrossRef
36.
Zurück zum Zitat Josting A, Wiedemann S, Franklin J et al (2003) Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3440–3446PubMedCrossRef Josting A, Wiedemann S, Franklin J et al (2003) Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3440–3446PubMedCrossRef
37.
Zurück zum Zitat Kalaycio M, Rybicki L, Pohlman B et al (2006) Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 24:3604–3610PubMedCrossRef Kalaycio M, Rybicki L, Pohlman B et al (2006) Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 24:3604–3610PubMedCrossRef
38.
Zurück zum Zitat Klimek VM (2013) Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol 20:137–143PubMedCrossRef Klimek VM (2013) Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol 20:137–143PubMedCrossRef
39.
Zurück zum Zitat Schmiegelow K, Levinsen MF, Attarbaschi A et al (2013) Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 31:2469–2476PubMedCrossRef Schmiegelow K, Levinsen MF, Attarbaschi A et al (2013) Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 31:2469–2476PubMedCrossRef
40.
Zurück zum Zitat Longhi A, Ferrari S, Tamburini A et al (2012) Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983–2006). Cancer 118:5050–5059. doi:10.1002/cncr.27493 (Epub 2012 Mar 13. PubMed PMID: 22415578)PubMedCrossRef Longhi A, Ferrari S, Tamburini A et al (2012) Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983–2006). Cancer 118:5050–5059. doi:10.1002/cncr.27493 (Epub 2012 Mar 13. PubMed PMID: 22415578)PubMedCrossRef
41.
Zurück zum Zitat Bartkowiak D, Humble N, Suhr P et al (2012) Second cancer after radiotherapy, 1981–2007. Radiother Oncol 105:122–126. doi:10.1016/j.radonc.2011.09.013 (Epub 2011 Oct 10. PubMed PMID: 21993405)PubMedCrossRef Bartkowiak D, Humble N, Suhr P et al (2012) Second cancer after radiotherapy, 1981–2007. Radiother Oncol 105:122–126. doi:10.1016/j.radonc.2011.09.013 (Epub 2011 Oct 10. PubMed PMID: 21993405)PubMedCrossRef
42.
Zurück zum Zitat Landier W, Bathia S (2008) Cancer survivorship: a pediatric perspective. Oncologist 13:1181–1192PubMedCrossRef Landier W, Bathia S (2008) Cancer survivorship: a pediatric perspective. Oncologist 13:1181–1192PubMedCrossRef
43.
Zurück zum Zitat Marees T, Moll AC, Imhof SM et al (2008) Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100:1771–1779PubMedCrossRef Marees T, Moll AC, Imhof SM et al (2008) Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100:1771–1779PubMedCrossRef
Metadaten
Titel
Spätfolgen onkologischer Therapie
verfasst von
Dr. H. Biersack
G. Brabant
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe 12/2013
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-013-2632-8

Weitere Artikel der Ausgabe 12/2013

Der Onkologe 12/2013 Zur Ausgabe

Neu im Fachgebiet Onkologie

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Warum junge Brustkrebspatientinnen die endokrine Therapie absetzen

15.07.2024 Mammakarzinom Nachrichten

Bei jungen Brustkrebspatientinnen ist die Wahrscheinlichkeit groß, dass sie eine adjuvante endokrine Therapie vorzeitig absetzen. In einer europäischen Kohorte wurden dafür zwei Risikofaktoren identifiziert, die bei der Behandlung berücksichtigt werden sollten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.